From €25820EUR$27,500USD£21,541GBP
- Report
- May 2024
Indonesia
From €2347EUR$2,500USD£1,958GBP
From €2347EUR$2,500USD£1,958GBP
- Report
- May 2024
Iceland
From €2347EUR$2,500USD£1,958GBP
- Report
- January 2024
Czech Republic
From €892EUR$950USD£744GBP
- Report
- September 2023
- 1450 Pages
Asia Pacific
From €13614EUR$14,500USD£11,358GBP
- Report
- September 2023
Middle East
From €7981EUR$8,500USD£6,658GBP
- Report
- August 2024
Global
From €25820EUR$27,500USD£21,541GBP
Beta 2 Microglobulin (B2M) is a protein found in the blood and urine of humans and other primates. It is used as a marker for diagnosing a variety of diseases, including kidney disease, multiple myeloma, and lymphoma. B2M is also used to monitor the progression of these diseases and to assess the effectiveness of treatments.
In the diagnostics market, B2M is used to detect and monitor a variety of diseases. It is used to measure the amount of B2M in the blood and urine, which can indicate the presence of certain diseases. B2M is also used to monitor the progression of these diseases and to assess the effectiveness of treatments.
The B2M diagnostics market is highly competitive, with a number of companies offering products and services. Some of the major players in the market include Abbott Laboratories, Siemens Healthineers, Roche Diagnostics, and Thermo Fisher Scientific. Show Less Read more